Answers are grounded in this paper and cite their sources.
In vitro evaluation of chitosan aldehyde derivatives shows anticancer activity in human cancer cell lines, indicating potential therapeutic applications.
Formulation of a new composite based on chitosan (Cs) with heterocyclic aldehydes (thiophen, ferrocene, and chloroquinoline) has been prepared and investigated via different techniques: FTIR, XRD, SEM, and TGA. The neutral red uptake assay was utilized to evaluate the in vitr o anticancer activity of chitosan aldehyde derivatives: Cs/thio-aldehyde(1) , Cs/ferro-aldehyde(2) , and Cs/chloro-aldehyde(3) on human cancer cell lines, namely Caco-2, MDA-MB-231, and HepG2. Compounds 1 , 2 , and 3 showed more inhibitory influence on Caco-2 and HepG2 growth, while compound 3 revealed more cytotoxicity contra MDA-MB-231 cells compared with doxorubicin. Relative to control values, the qRT-PCR results showed that compounds 1 and 3 significantly affected the up regulation of JNK and p53 genes and the down regulation of the ERK gene in treated cells. Thus, these results demonstrated that the examined compounds 1 and 3 triggered apoptosis via controlling the JNK/ERK-p53 signaling axis and decreased the growth of Caco-2, MDA-MB-231, and HepG2 cells. Also, these biological studies confirmed through molecular docking and DFT calculation with different proteins and showed that Cs/thio (1) is the most reactive compound with short bond length and less energy gap (Eg) (0.18518) than Cs/chloro (3) with energy gap (Eg) (-0.71892) descriptors, which showed excellent correlation with experimental results.
No takes yet. Share an insight, caveat, or question.
Elsayed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: